SRI International and Blanca Pharmaceuticals will jointly develop Blanca's carbacephem antibiotic drug candidates, now in late-stage preclinical development. The two compounds under study are ideal candidates for empiric therapy against hospital-acquired infections when the causative pathogen is unknown, the companies reports.
BP-101 and BP-102 have broad-spectrum bactericidal activity against gram-positive bacteria, such as methicillin-resistant staphylococcus aureus and epidermidis (MRSA/E), penicillin-resistant streptococcus pneumoniae (PRSP), and vancomycin-resistant enterococcus (VRE), as well as most gram-negative bacteria, according to the companies.
Blanca's compounds will initially be developed as parenteral formulations. The company is also researching oral formulations for the primary treatment of community-acquired infections and oral step-down therapy for hospitalized patients.
Upon IND application filing, Blanca will retain worldwide, exclusive commercialization rights to the compounds. SRI will participates in the development and incubation efforts and has an option to take an ownership interest in Blanca.